Palvella Therapeutics

Palvella Therapeutics Overview

  • Founded
  • 2015
Founded
  • Status
  • Private
  • Latest Deal Type
  • Series C
  • Latest Deal Amount
  • $45M
Latest Deal Amount
  • Investors
  • 10

Palvella Therapeutics General Information

Description

Developer of therapeutic agents intended to find solutions for rare and ultra-rare diseases. The company is engaged in developing novel, disease-modifying therapy to treat pachyonychia congenita, an ultra-orphan, a chronically debilitating genetic disease for which no treatments currently exist, enabling patients to get the best treatment for diseases and lead a better life.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 125 Strafford Avenue
  • Suite 360
  • Wayne, PA 19087
  • United States
+1 (484) 000-0000

Palvella Therapeutics Timeline

2017201820192020
Financing Round
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Palvella Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series C) 28-May-2020 $45M 000.00 Completed Clinical Trials - Phase 3
5. Early Stage VC 12-Aug-2019 00.000 000.00 Completed Clinical Trials - Phase 2
4. Corporate 18-Dec-2018 0000 000.00 Completed Clinical Trials - General
3. Early Stage VC 14-Jun-2018 00.000 00.000 Completed Clinical Trials - General
2. Grant $2.5M Completed Clinical Trials - General
1. Early Stage VC 01-Jun-2017 $2.5M $2.5M Completed Clinical Trials - General

Palvella Therapeutics Competitors (37)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing
Amount
Sino Biological Formerly VC-backed Beijing, China 000 00000 00000000 00000
00000 000000000000 Formerly PE-Backed Singapore, Singapore 00 00000 00000000
0000000 Venture Capital-Backed San Diego, CA 00 000.00 00000 00000 000.00
0000000 00000000 0 Venture Capital-Backed Beijing, China 00000 00000000000 00000
00000 000000000 Formerly VC-backed Boulder, CO 000 00000 000000&0 00000

Palvella Therapeutics Executive Team (4)

Name Title Board Seat Contact Info
Wesley Kaupinen Chief Executive Officer, President & Board Member
Kathleen McGowan Chief Financial Officer
Renee Mundy Ph.D Vice President, Portfolio Strategy
Braham Shroot Ph.D Chief Scientific Officer

Palvella Therapeutics Board Members (11)

To view Palvella Therapeutics‘s full board member team, request access »
Name Representing Role Since
Cory Freedland Ph.D Samsara BioCapital Board Member 000 0000
David Tierney MD Self Board Member 000 0000
Elaine Heron Ph.D Self Board Member 000 0000
George Jenkins Self Chairman 000 0000
John Doux MD Self Board Member 000 0000

Palvella Therapeutics Investors (10)

To view Palvella Therapeutics‘s full investor history, request access »
Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Adams Street Partners Fund of Funds Minority 000 0000 000000 0
BVF Partners Hedge Fund Minority 000 0000 000000 0
CAM Capital Asset Manager Minority 000 0000 000000 0
Nolan Capital Family Office Minority 000 0000 000000 0
Opaleye Management Other Minority 000 0000 000000 0

Ready to get started?

Request a free trial